Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study

ObjectivesLimited evidence is available on the co-administration of treatment for hepatitis C virus (HCV) and multidrug-resistant tuberculosis (MDR-TB). The objective of this study is to assess safety and effectiveness of concomitant treatment of chronic HCV-infection and MDR-TB.MethodsWe performed...

Full description

Bibliographic Details

Published in:	The Journal of infection Vol. 84; no. 6; pp. 834 - 872
Main Authors:	Tunesi, Simone, Dû, Damien Le, Gualano, Gina, Millet, Joan-Pau, Skrahin, Aliaksandr, Bothamley, Graham, Casas, Xavier, Goletti, Delia, Lange, Christoph, Musso, Maria, Palmieri, Fabrizio, Pourcher, Valérie, Rioux, Christophe, Skrahina, Alena, Veziris, Nicolas, Viatushka, Dzmitry, Jachym-Fréchet, Mathilde, Guglielmetti, Lorenzo, Marigot-Outtandy, Dhiba, Lescure, Xavier, Dubert, Marie, Yazdanpanah, Yazdan, Caumes, Eric, Choinier, Pascaline, Haddad, Elie, Kowalczyk, Jakub, Laurichesse, Hélène, Lesens, Olivier, Aubry, Alexandra, Bonnet, Isabelle, Morel, Florence
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.06.2022 Elsevier
Subjects:	Antitubercular Agents - therapeutic use Hepatitis C - drug therapy Human health and pathology Humans Infectious diseases Life Sciences Pulmonology and respiratory tract Rifampin - therapeutic use Tuberculosis, Multidrug-Resistant - drug therapy MDR antiviral tuberculosis
ISSN:	0163-4453, 1532-2742, 1532-2742
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!